ProQR Therapeutics NV
PRQR2.140USD
-0.070-3.17%
收盘 12/22, 16:00（美东）报价延迟15分钟
230.50M总市值
亏损市盈率 TTM
关于 ProQR Therapeutics NV 公司
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NV简介
公司代码PRQR
公司名称ProQR Therapeutics NV
上市日期Sep 18, 2014
CEOde Boer (Daniel Anton)
员工数量166
证券类型Ordinary Share
年结日Sep 18
公司地址Zernikedreef 9
城市LEIDEN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Netherlands
邮编2333 CK
电话31881667000
网址https://www.proqr.com/
公司代码PRQR
上市日期Sep 18, 2014
CEOde Boer (Daniel Anton)
ProQR Therapeutics NV公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Begona Carreno, Ph.D.
Ms. Begona Carreno, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Eli Lilly and Company
16.04%
Van Herk Investments
13.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
4.74%
Affinity Asset Advisors LLC
3.42%
其他
56.26%
持股股东
持股股东
占比
Eli Lilly and Company
16.04%
Van Herk Investments
13.60%
Adage Capital Management, L.P.
5.94%
Privium Fund Management BV
4.74%
Affinity Asset Advisors LLC
3.42%
其他
56.26%
股东类型
持股股东
占比
Hedge Fund
18.45%
Corporation
16.04%
Family Office
13.60%
Investment Advisor
9.89%
Investment Advisor/Hedge Fund
5.04%
Research Firm
3.13%
Individual Investor
2.00%
Bank and Trust
0.03%
其他
31.83%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
111
41.68M
39.56%
-4.38M
2025Q2
122
61.04M
57.95%
-6.05M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
2023Q2
170
45.68M
56.49%
-13.40M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Eli Lilly and Company
16.90M
16.04%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
14.33M
13.6%
+2.13M
+17.44%
Sep 29, 2025
Adage Capital Management, L.P.
6.60M
6.27%
-1.50M
-18.52%
Jun 30, 2025
Privium Fund Management BV
5.00M
4.74%
+11.93K
+0.24%
Jun 30, 2025
Affinity Asset Advisors LLC
3.50M
3.32%
+215.00K
+6.55%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.06M
2.91%
+1.70M
+124.72%
Jun 30, 2025
abrdn Inc.
1.85M
1.76%
--
--
Jun 30, 2025
Sio Capital Management, LLC
2.08M
1.97%
+20.55K
+1.00%
Jun 30, 2025
Kynam Capital Management LP
1.65M
1.57%
-100.54K
-5.75%
Jun 30, 2025
Dafna Capital Management, LLC
1.57M
1.49%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Avantis International Small Cap Equity ETF
0.01%
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
占比0.01%
Avantis International Small Cap Value ETF
占比0%
Invesco NASDAQ Future Gen 200 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
ProQR Therapeutics NV的前五大股东是谁？
ProQR Therapeutics NV 的前五大股东如下：
Eli Lilly and Company持有股份：16.90M，占总股份比例：16.04%。
Van Herk Investments持有股份：14.33M，占总股份比例：13.60%。
Adage Capital Management, L.P.持有股份：6.60M，占总股份比例：6.27%。
Privium Fund Management BV持有股份：5.00M，占总股份比例：4.74%。
Affinity Asset Advisors LLC持有股份：3.50M，占总股份比例：3.32%。
Eli Lilly and Company持有股份：16.90M，占总股份比例：16.04%。
Van Herk Investments持有股份：14.33M，占总股份比例：13.60%。
Adage Capital Management, L.P.持有股份：6.60M，占总股份比例：6.27%。
Privium Fund Management BV持有股份：5.00M，占总股份比例：4.74%。
Affinity Asset Advisors LLC持有股份：3.50M，占总股份比例：3.32%。
ProQR Therapeutics NV的前三大股东类型是什么？
ProQR Therapeutics NV 的前三大股东类型分别是：
Eli Lilly and Company
Van Herk Investments
Adage Capital Management, L.P.
Eli Lilly and Company
Van Herk Investments
Adage Capital Management, L.P.
有多少机构持有ProQR Therapeutics NV(PRQR)的股份？
截至2025Q3，共有111家机构持有ProQR Therapeutics NV的股份，合计持有的股份价值约为41.68M，占公司总股份的39.56%。与2025Q2相比，机构持股有所增加，增幅为-18.39%。
哪个业务部门对ProQR Therapeutics NV的收入贡献最大？
在--，--业务部门对ProQR Therapeutics NV的收入贡献最大，创收--，占总收入的--%。
